| Structure-based design of hepatitis C virus E2 glycoprotein improves serum binding and cross-neutralization BG Pierce, ZY Keck, R Wang, P Lau, K Garagusi, K Elkholy, EA Toth, ... Journal of virology 94 (22), 10.1128/jvi. 00704-20, 2020 | 23 | 2020 |
| Design of a native-like secreted form of the hepatitis C virus E1E2 heterodimer JD Guest, R Wang, KH Elkholy, A Chagas, KL Chao, TE Cleveland IV, ... Proceedings of the National Academy of Sciences 118 (3), e2015149118, 2021 | 22 | 2021 |
| Ibrutinib potentiates antihepatocarcinogenic efficacy of sorafenib by targeting EGFR in tumor cells and BTK in immune cells in the stroma CH Lin, KH Elkholy, NA Wani, D Li, P Hu, JM Barajas, L Yu, X Zhang, ... Molecular cancer therapeutics 19 (2), 384-396, 2020 | 21 | 2020 |
| Ibrutinib in combination with sorafenib synergistically inhibits hepatocarcinogenesis by targeting EGFR signaling pathway A Noonan, CH Lin, K Elkholy, N Wani, D Li, P Hu, JM Barajas, LB Yu, ... EUROPEAN JOURNAL OF CANCER 103, E131-E132, 2018 | | 2018 |
| Ibrutinib and sorafenib synergistically inhibit HCC growth in preclinical models K Ghoshal, C Lin, K Elkholy, NA Wani, D Li, JM Barajas, P Hu, X Zhang, ... Cancer Research 78 (13_Supplement), 3470-3470, 2018 | | 2018 |
| Anti-Tumorigenic and Immunomodulatory Effects of Ibrutinib Against Hepatocellular Carcinoma KH Elkholy The Ohio State University, 2017 | | 2017 |
| Ibrutinib in Combination with Sorafenib Synergistically Inhibits Proliferation and Survival of Hepatocellular Carcinoma Cells by Targeting EGFR Signaling Pathway CH Lin, N Wani, K Elkholy, K Ghoshal | | 2017 |
